08:29 AM EDT, 05/15/2024 (MT Newswires) -- Blackstone (BX) said Wednesday its Blackstone Life Sciences unit has launched a clinical-stage drug development company focusing on immunology and inflammation.

Uniquity Bio, "is emerging from stealth" with a US Food and Drug Administration acceptance of its phase 2 investigational new drug application for an anti-TSLP monoclonal antibody, solrikitug, Blackstone said.

To advance the asset in various indications, Blackstone Life Sciences committed financing of up to $300 million for Uniquity Bio, according to the Blackstone.

The company said Uniquity Bio will launch phase 2 clinical trials in chronic obstructive pulmonary disease next month.

Price: 125.80, Change: -0.17, Percent Change: -0.13